Altogether, these results indicate that TAS3681 exerts significant antitumor effects against enzalutamide‐resistant PCa xenografts, accompanied by a reduction of AR‐FL and AR‐Vs levels in tumors. This evidence concerns the gene AR and posterior cortical atrophy.